Abstract 219P
Background
Radical radiotherapy is the mainstay of bladder preservation treatment for muscle-invasive bladder cancer (MIBC) patients. The concurrent use of radiosensitisers improves patient outcome (Caffo et al., 2016, Hoskin et al., 2010). However, different factors may preclude patients from receiving radiosensitisers. This retrospective study evaluates the survival and toxicity outcomes of bladder preservation treatment in a tertiary cancer centre.
Methods
Patients treated with radical radiotherapy from 2010 to 2017 were divided into two groups depending on whether they received radiosensitisers in addition to radiotherapy. The primary outcome was overall survival (OS) and the secondary outcome was rate of late toxicities. Kaplan-Meier analyses were used to analyse OS. Late genitourinary (GU) and gastrointestinal (GI) toxicities were defined as treatment-related toxicities at 1-year post-treatment, assessed on the LENT/SOMA scale.
Results
A total of 428 patients were included in the survival analysis. 303 patients had combination treatment while 125 patients had radiotherapy alone. Patients in the combination group were younger (median age 72 vs 81, p < 0.001), have better performance status (PS 0-2 298 (95%) vs 115 (92%), p < 0.001), and fewer comorbidities compared to patients in radiotherapy alone group. The median follow-up for this study was 56 months. The median OS was 76 months (95% CI: 66-NA) in radiosensitiser group compared to 13 months in radiotherapy only group (95% CI: 13-21) (p < 0.001, HR = 3.09 (95% CI: 2.32-4.12)). As shown in the table, the incidence of late toxicity was low in both groups and formal analysis could not be carried out.
Table: 219P Rates of late toxicities following radical radiotherapy
Combination (N = 303) | Radiotherapy (N = 125) | |
---|---|---|
GU Toxicity | ||
Any grade | 119 (39.3%) | 2 (1.6%) |
Grade 3-4 | 4 (1.3%) | 1 (0.8%) |
GI Toxicity | ||
Any grade | 133 (43.9%) | 2 (1.6%) |
Grade 3-4 | 4 (1.3%) | 0 (0%) |
Conclusions
The survival outcome with radiosensitisation in this real-world retrospective study is in keeping with published data. Bladder preservation is effective with minimal long-term toxicities. Patients with localised MIBC should be offered the option of bladder preservation treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Radiotherapy-Related Research Group, The Christie Hospital NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
19P - Silymarin functionalized quantum cores as selective inhibitor of polo-like kinase 1, and preclinical antitumor activity in human breast cancer xenografts
Presenter: Manickam Paulpandi
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract